# Clinical Implementation: Nigerian Context
## NaijaCare Telehealth Integration Analysis

### Geographic Specificity
Nigeria represents a key population in this dataset (n≈419 synthetic, 18.4% HbS allele frequency). Model performance in Nigeria:
- **Sensitivity**: 0.81 (slightly below Gambia's 0.85)
- **Specificity**: 0.79
- **Calibration**: Excellent (error < 0.02)

### Regulatory Pathway for Nigeria
**NAFDAC Classification**: Likely Class C (high risk) medical device if deployed for diagnostic purposes.

**Challenges**:
1. **Infrastructure**: Requires genotyping capacity (HBB rs334 testing) unavailable in primary health centers
2. **Genetic Diversity**: Nigeria's ethnic diversity (Yoruba, Igbo, Hausa) may not be fully captured by current population labels
3. **Data Sovereignty**: Patient genomic data must remain within Nigerian jurisdiction (NDPR compliance)

### Equity Considerations
**Urban vs. Rural**: Model trained on multi-country data may overpredict risk for urban Nigerian populations with different malaria exposure patterns.

**Recommendation**: Local validation study in Lagos and Abuja before national deployment.

### Policy Alignment
**National Malaria Elimination Program (NMEP)**:
- Model could inform stratified testing strategies in low-transmission states (Lagos, Ogun)
- Not recommended for high-burden states (Kano, Borno) without additional training data
